Home / Inspections / 1079961

FDA Inspection 1079961 — Hikma Pharmaceuticals USA, Inc.

Hikma Pharmaceuticals USA, Inc. — FEI 2250102

The FDA completed an inspection of Hikma Pharmaceuticals USA, Inc. on February 1, 2019 in Eatontown, NJ. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.

Inspection Details

Classification
No Action Indicated (NAI) (NAI)
End Date
February 1, 2019
Fiscal Year
2019
Product Type
Drugs
Project Area
Bioresearch Monitoring
Location
Eatontown, NJ (United States)

Additional Details

Postmarket Adverse Drug Experience (PADE)

Facility

Other inspections at this facility

  • 1054739 (NAI Fri Apr 13 2018 00:00:00 GMT+0000 (Coordinated Universal Time))
  • 976090 (NAI Thu Jul 07 2016 00:00:00 GMT+0000 (Coordinated Universal Time))
  • 942928 (NAI Thu Sep 10 2015 00:00:00 GMT+0000 (Coordinated Universal Time))
  • 864847 (VAI Wed Feb 26 2014 00:00:00 GMT+0000 (Coordinated Universal Time))
  • 829253 (OAI Fri Jun 07 2013 00:00:00 GMT+0000 (Coordinated Universal Time))

Recent compliance actions

FDA data resources